Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.78 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.66 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 4/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13406369 | 0.86 | PIK3CA (0.77) | PIK3CAPIK3CBPIK3CGPIK3CDATR | |
| SCHEMBL13406371 | 0.85 | PIK3CA (0.93) | PIK3CAPIK3CBPIK3CGATRTYK2 | |
| SCHEMBL13406364 | 0.85 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CGPIK3CDATR | |
| SCHEMBL1310090 | 0.84 | PIK3CA (0.56) | PIK3CAPIK3CBPIK3CGPIK3CDATR | |
| SCHEMBL13336861 | 0.84 | PIK3CA (0.79) | PIK3CAPIK3CBPIK3CGPIK3CDATR | |
| SCHEMBL13119642 | 0.84 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CGPIK3CDATR | |
| SCHEMBL3560625 | 0.82 | PIK3CA (0.78) | PIK3CAPIK3CBPIK3CGPIK3CDATR | |
| SCHEMBL7906648 | 0.81 | PIK3CA (0.51) | PIK3CAPIK3CBPIK3CGPIK3CDATR | |
| SCHEMBL13406351 | 0.77 | PIK3CA (0.67) | PIK3CAPIK3CBPIK3CGPIK3CDTYK2 | |
| SCHEMBL1311145 | 0.77 | PIK3CA (0.53) | PIK3CAPIK3CBPIK3CGPIK3CDATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-8569296-B2 | PI3K (delta) selective inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8513221-B2 | PI3K isoform selective inhibitors | Xcovery Holding, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513221-B2 | PI3K isoform selective inhibitors | Xcovery Holding, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC | 2012-08-09 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY LLC | 2011-06-02 | — | — | US | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | PIK3CD, PIK3CA, PIK3R5 | PIK3CA 2/4885PIK3CB 6/4885PIK3CG 5/4885 |
| US-20090042884-A1 | Pharmaceutical Compounds | PIK3CA, JAK1, PIK3R1 | PIK3CA 1/4885PIK3CB 10/4885PIK3CG 15/4885 |
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | PIK3CA 28/4885PIK3CB 13/4885PIK3CG 14/4885 |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | PIK3CD, PIK3CA, PIK3R5 | PIK3CA 2/4885PIK3CB 6/4885PIK3CG 5/4885 |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CB 9/4885PIK3CG 7/4885 |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | PI4KA, PIK3CA, PIKFYVE | PIK3CA 2/4885PIK3CB 15/4885PIK3CG 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.